96 related articles for article (PubMed ID: 24556355)
1. Fabry disease: dose matters.
Warnock DG; Mauer M
J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
[No Abstract] [Full Text] [Related]
2. Two successful pregnancies in a woman with Fabry continuing enzyme replacement therapy.
Paydas S; Akcabay C
Ther Apher Dial; 2024 Apr; 28(2):329-330. PubMed ID: 37941141
[No Abstract] [Full Text] [Related]
3. Recall urticaria with infusion of agalsidase beta.
Yedidi RS; Bernstein JA
Ann Allergy Asthma Immunol; 2023 Nov; 131(5):672-674. PubMed ID: 37557952
[No Abstract] [Full Text] [Related]
4. Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.
Beer AM; Cooper-Knock J; Fletcher S; Brown-Wright SH; Nandakumar TP; Shaw PJ
Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):614-616. PubMed ID: 27094629
[No Abstract] [Full Text] [Related]
5. A Vitamin C Renal Leak in Fabry Disease: The Rare Informs the Common.
Monti DA
J Nutr; 2023 Jul; 153(7):1839-1840. PubMed ID: 36806448
[No Abstract] [Full Text] [Related]
6. Characteristic cardiac capillary pericytes in a Fabry disease patient receiving enzyme replacement therapy.
Kanamori H; Nakashima T; Yoshida A; Miyazaki T; Mikami A; Okura H
Hellenic J Cardiol; 2024; 75():101-102. PubMed ID: 37268104
[No Abstract] [Full Text] [Related]
7. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease.
Thomas AS; Hughes DA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():88-101. PubMed ID: 25345090
[TBL] [Abstract][Full Text] [Related]
9. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.
Juan P; Hernan A; Beatriz SA; Gustavo C; Antonio M; Eduardo T; Raul D; Margarita L; Mariana B; Daniela G; Marina S
JIMD Rep; 2014; 16():7-14. PubMed ID: 24850233
[TBL] [Abstract][Full Text] [Related]
11. Cerebrovascular involvement in Fabry disease: current status of knowledge.
Kolodny E; Fellgiebel A; Hilz MJ; Sims K; Caruso P; Phan TG; Politei J; Manara R; Burlina A
Stroke; 2015 Jan; 46(1):302-13. PubMed ID: 25492902
[No Abstract] [Full Text] [Related]
12. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
13. Ocular signs correlate well with disease severity and genotype in Fabry disease.
Pitz S; Kalkum G; Arash L; Karabul N; Sodi A; Larroque S; Beck M; Gal A
PLoS One; 2015; 10(3):e0120814. PubMed ID: 25781336
[TBL] [Abstract][Full Text] [Related]
14. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
15. Clinical prodromes of neurodegeneration in Anderson-Fabry disease.
Löhle M; Hughes D; Milligan A; Richfield L; Reichmann H; Mehta A; Schapira AH
Neurology; 2015 Apr; 84(14):1454-64. PubMed ID: 25762709
[TBL] [Abstract][Full Text] [Related]
16. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
17. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
Pisani A; Riccio E; Sabbatini M
Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
[No Abstract] [Full Text] [Related]
18. Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.
Tsuboi K; Yamamoto H
Genet Med; 2014 Oct; 16(10):766-72. PubMed ID: 24651606
[TBL] [Abstract][Full Text] [Related]
19. Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.
Goker-Alpan O; Nedd K; Shankar SP; Lien YH; Weinreb N; Wijatyk A; Chang P; Martin R
JIMD Rep; 2015; 23():7-15. PubMed ID: 25822820
[TBL] [Abstract][Full Text] [Related]
20. Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice.
Shen JS; Meng XL; Wight-Carter M; Day TS; Goetsch SC; Forni S; Schneider JW; Liu ZP; Schiffmann R
Hum Mol Genet; 2015 Jun; 24(11):3181-91. PubMed ID: 25701874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
